Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Conditions

• Medullary Thyroid Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• No treatment given — OTHER
  No treatment given

Study Details

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Key Dates

First listed

Jul 20, 2026

Start date

Dec 31, 2025

Status verified

Jul 2026

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

93,600,000 participants (estimated)

Arms

• Arm: Long-acting GLP-1 RA Exposed Cohort
  Participants will be eligible for inclusion in this cohort if they have at least one dispensed prescription for a LA GLP-1 RA therapy during the study patient selection period.
• Arm: T2D Active Comparator 1 Cohort
  Participants will be included in this cohort if they fill at least one dispensed prescription for SGLT2 or DPP-4 inhibitors during the study patient selection period with no evidence of SGLT2 or DPP-4 inhibitors and without LA GLP-1 RA use during the prior 12-month lookback period.
• Arm: T2D Active Comparator 2 Cohort
  Participants will be included in this cohort if they fill at least one dispensed prescription for any antidiabetic medications (including SGLT2 or DPP-4 inhibitors), other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.
• Arm: Overweight/Obesity Active Comparator Cohort
  Participants will be included in this cohort if they fill at least one dispensed prescription for anti-obesity medications, other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.

Primary Outcome Measure

Time to first occurence of Medullary Thyroid Carcinoma (MTC) [ Time Frame: From day 1 up to 15 years ]

Locations (1)

Find similar trials in Parsippany, NJ

Related Studies

• An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
  Enrolling By Invitation · Novo Nordisk A/S · Morgantown, West Virginia